18 Dec 2015 The markets have had little on their mind recently bar that ‘momentous’ decision to raise US interest rates for the first time since the financial crisis. Following that, attention has come back to emerging markets and their old buddies, commodities. Of course, market volatility is always good…
18 December 2015 It was a protracted build up to say the least. And the Y2K-like fears the world would implode after the first US interest rate rise in almost a decade proved unfounded with the muted market reaction to Janet Yellen finally pulling the trigger Wednesday evening. While we would normally cheer heightened volatility…
Aktien Frankfurt: Anleger machen nach Rally Kasse Finanzen.net – 18 Dec http://www.finanzen.net/nachricht/aktien/Aktien-Frankfurt-Anleger-machen-nach-Rally-Kasse-4660717 U.S. stocks poised for another day in red after oil, Asia tremors Marketwatch – 18 Dec http://www.marketwatch.com/story/us-stocks-poised-for-another-day-in-red-after-oil-asia-tremors-2015-12-18 Brief relief as focus reverts to growth grief Proactive Investors – 18 Dec http://www.proactiveinvestors.co.uk/columns/morning-market-pulse/23883/brief-relief-as-focus-reverts-to-growth-grief-23883.html Fed rate hike boosts…
17 Dec You’re welcome to, but I won’t be, because I like to not be thinking about that stuff while trying to digest a double helping of sprouts. But for those of you considering it, bravo! Because Christmas is home to the Santa Rally – one example of a seasonal market phenomenon. Why do stock…
17 December 2015 Investors in specialty chemicals focused Elementis (ELM) are failing to benefit from the Fed-hike led global rally, dropping back below the key 230p level after a disappointingly bearish full-year pre-close trading statement containing explicit reference to challenging markets, continued currency headwinds and unfortunate need to…
December 14 2015 With returns from healthcare R&D halving to multi-year lows according to Deloitte it makes sense that consolidation is rife within a sector that spends dearly for the ‘chance of a chance’ of success, years in advance of any likely revenue generation. This despite drug approvals at their highest…